Találati lista | Tudóstér

001-es BibID:	BIBFORM090205
035-os BibID:	(WOS)000608951800001 (Scopus)85099552143
Első szerző:	Fagyas Miklós (orvos)
Cím:	Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis : implications for ACE2 as a biomarker for the severity of COVID-19 / Fagyas Miklós, Kertész Attila, Mányiné Siket Ivetta, Bánhegyi Viktor, Kracskó Bertalan, Szegedi Andrea, Szokol Miklós, Vajda Gusztáv, Rácz Ildikó, Gulyás Hajnalka, Szkibák Noémi, Rácz Vivien, Csanádi Zoltán, Papp Zoltán, Tóth Attila, Sipka Sándor
Dátum:	2021
ISSN:	2509-2715 2509-2723
Megjegyzések:	Coronavirus disease 2019 (COVID-19) has a high mortality in elderly patients with preexisting cardiovascular diseases. The cellular receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the angiotensin converting enzyme 2 (ACE2), thereby implicating a link between cardiovascular diseases and SARS-CoV-2 susceptibility. Aortic stenosis (AS) represents a chronic inflammatory state with severe cardiovascular complications in the elderly, a prime condition for COVID-19 mortality. The circulating ACE2 levels were measured in 111 patients with severe AS and compared to patients with hypertension and healthy individuals. About 4-times higher circulating ACE2 activity was found in patients with severe AS than in hypertensives or healthy individuals (88.3?61.6., n=111, 20.6?13.4, n=540 and 16.1?7.4 mU/L, n=46, respectively). Patients with severe AS were older than patients with hypertension (80?6 years vs. 60?15 years, P<0.05). Serum ACE2 activity correlated negatively with the left ventricular ejection fraction, aortic root area, TAPSE and positively with the right ventricular systolic pressure, cardiac diameters in patients with AS. In contrast, circulating ACE2 activity was independent of the blood pressure, peak flow velocity at the aortic root, kidney function (GFR) and inflammatory state (CRP). We found no effect of RAAS inhibitory drugs on the serum ACE2 activity in this group of patients. Our results illustrate circulating ACE2 as a potential interface between chronic inflammation, cardiovascular disease and COVID-19 susceptibility. Elderly patients with AS have markedly elevated ACE2 levels together with altered left and right ventricular functions, which may pose higher risks during COVID-19. Our clinical data do not support a role for RAAS inhibitors in regulating circulating ACE2 levels. taa, km
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk ACE2 TAVI COVID-19 aortic stenosis age
Megjelenés:	GeroScience. - 43 : 1 (2021), p. 19-29. -
További szerzők:	Kertész Attila Béla (1973-) (kardiológus) Mányiné Siket Ivetta (1962-) (laborasszisztens) Bánhegyi Viktor (1991-) (kardiológus) Kracskó Bertalan (1986-) (orvos) Szegedi Andrea (kardiológus) Szokol Miklós (1971-) (kardiológus) Vajda Gusztáv (1956-) (kardiológus) Rácz Ildikó (1973-) (kardiológus) Gulyás Hajnalka Szkibák Noémi Rácz Vivien Csanádi Zoltán (1960-) (kardiológus) Papp Zoltán (1965-) (kardiológus, élettanász) Tóth Attila (1971-) (biológus) Sipka Sándor ifj. (1980-) (orvos)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00043 GINOP EFOP-3.6.2-16-2017-00006 EFOP GINOP-2.3.2-15-2016-00050 GINOP OTKA-116940 OTKA NKFIH-K132623 Egyéb NKFIH-FK128809 Egyéb ED_18-1-2019-0028 Egyéb
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM040599
Első szerző:	Nieminen, Markku S.
Cím:	Effects of Levosimendan on the Energy Balance : Preclinical and Clinical Evidence / Markku S. Nieminen, Piero Pollesello, Gusztáv Vajda, Zoltán Papp
Dátum:	2009
Megjegyzések:	Levosimendan is a novel inodilator agent, which enhances myocardial performance without substantial changes in oxygen consumption. The combination of positive inotropic and vasodilator effects of levosimendan relates to its Ca-sensitizing and K channel opening effects. Levosimendan is one of the best documented pharmacological agents used in the management of acute heart failure syndromes. Interest in levosimendan has recently been renewed owing to its potential in supporting cardiac function in patients with ischemic heart disease and cardiogenic or septic shock. It has been also demonstrated that levosimendan can be used as a bridge therapy for the perioperative phase of cardiac surgery. The ability of levosimendan to improve myocardial function without substantially increasing oxygen consumption may appear paradoxical but is indeed possible via improved efficacy, not only with regard to the effects on the contractile apparatus of the cardiomyocytes but also when its composite hemodynamic effects are considered. The energy balance equation, therefore, should take into account the effect of levosimendan on all energy-consuming and energy-producing paths. Moreover, levosimendan-evoked KATP channel opening may possess favorable effects on mitochondrial adenosine triphosphate synthesis conferring cardioprotection during ischemic insults.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of Cardiovascular Pharmacology and Therapeutics. - 53 : 4 (2009), p. 302-310. -
További szerzők:	Pollesello, Piero Vajda Gusztáv (1956-) (kardiológus) Papp Zoltán (1965-) (kardiológus, élettanász)
Pályázati támogatás:	K 68363 OTKA
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: